August 03, 2018
KEDPLASMA USA, one of the world’s leading companies partaking in the global platelet and plasma market share, has recently added two plasma collection centers to its growing global network – one in Atlanta, and another in Longview. If reports are to be believed, both the centers are considered significantly important to the company for its strategic expansion that will cater to the accelerated regional demand for plasma.
The aforementioned instance further reflects how the industry players are strengthening their positions in this business space through a spate of strategies such as network expansion, partnerships, and collaborations. As KEDPLASMA USA expands its operations, it is overt that more patients across the United States will have access to the important therapies that are derived from the use of plasma & platelets in drug discovery.
The extensive use of platelets and plasma in a range of therapies used for treating rare diseases and life-threatening conditions such as primary immune deficiency, thrombocytopenia, hemophilia, prevention of Rh sensitization, rabies, hepatitis B, and coagulation factor deficiencies is significantly influencing the growth statistics of platelet and plasma market. The escalated demand in use of plasma during the outbreak on Ebola virus is one of the significant instances bearing testimony to the above said fact.
Therapeutic protein drug development to strongly influence platelet and plasma market growth
Global pharmaceutical companies are progressively focusing on research & development using proteins in search of novel therapeutics drugs. The significant attention by researchers and drug developers has resulted in considerable advances in the production and usage of therapeutic proteins in recent years – a factor significantly propelling platelet and plasma market. Analysts deem that the latest advances in protein-engineering technologies have allowed drug developers to exploit and fine-tune the desirable functional characteristics of proteins. These advances in pharmaceutical biotechnology and genetic engineering have had a major impact on platelet and plasma industry and the companies operating in this business sphere are further likely to adopt expansion strategies to cash in on the ongoing development in protein drug manufacturing.
Speaking along similar lines it is prudent to mention that the platelet and plasma industry is recently ablaze with Abzena plc’s recent scoop mentioning the company’s protein engineering agreement with NYU Langone Health, one of America’s leading medical centers. This agreement according to sources, is expected to help NYU Langone accelerate its protein engineering services and develop novel biopharmaceutical therapeutics to treat a number of clinical indications including genetic disorders, cancer, and autoimmunity/inflammation disorders.
Soaring blood transfusion rates to drive platelet and plasma market
The growth of platelet and plasma market is further impacted by the escalated blood transfusion rates across the globe. According to a World Health Organization report (2010), based on information from 173 countries, more than 93 million blood donations are provided by all types of blood donors annually. Estimates also claim that the average yearly collection per blood center is around 30,000 across the developed countries, 3700 across the developing countries, and over 7500 in the transitional economies. The data goes on to validate that the growing number of initiatives to source plasma collection as well as use the plasma protein therapies in the treatment of rare diseases will ultimately have a favorable impact on the platelet and plasma industry expansion.
The contribution of Europe toward global platelet and plasma market size
Europe is one such region which is witnessing a significant increase in blood transfusion rates. Favorable R&D scenarios to treat rare autoimmune blood disorders such as thrombotic thrombocytopenic purpura (TTP) have impelled the industry players to invest in this region. Recently for instance, Sanofi has closed on a EU approval of a new drug Cablivi that has been recommended for a TTP disorder in Europe. It is prudent to mention that currently, the only treatment available for a TTP patients is through plasma exchange and immunosuppressive drugs that have severe side effects. Quite overtly, the approval of the new drug and further demand for drug discovery has set Europe to be a major revenue pocket for the global platelet and plasma market.
Rising blood transfusion rates in the continent are a principal driver for the growth of Europe platelet and plasma market. As per EU estimates, in 2017 alone, more than 20 million units of blood or blood components were transfused.
The positive results of plasma-based clinical trials in drug discovery and treatment of rare diseases has rapidly led to widespread expansion of this business sphere across many countries including the U.S., Australia, Canada, China, and the UK that has greatly increased the market for platelets and plasma. It wouldn’t be wrong to quote that these developments have had a profound impact on the remuneration portfolio of the global platelet and plasma market, which indeed will continue to crave a lucrative roadmap in the years ahead.